For moderate to severe ulcerative colitis (UC) in adult TNFi-IR patients.1

The Gastro Edition:
UC Relief* Starts Here

Welcome to RINVOQ REELS —
a video library featuring your peers discussing clinical
data and sharing opinions about treating UC

Welcome to
RINVOQ REELS — a video 
library featuring your 
peers discussing clinical data and sharing opinions about treating UC

CLINICAL PROFILE  

Dr. Miguel Regueiro and Dr. Remo Panaccione present an overview of the RINVOQ clinical profile with a focus on the well‑studied safety results in UC.

Stringent Endpoints in UC  
Stringent Endpoints  
in UC  

Dr. Miguel Regueiro and Dr. Remo Panaccione discuss evolving treatment guidelines and the stringent endpoints that RINVOQ achieved including endoscopic and histo-endoscopic outcomes.

The relationship between histo-endoscopic mucosal improvement to disease progression and long-term outcomes was not evaluated.

*Clinical response per partial modified Mayo Score is a composite of Mayo stool frequency and rectal bleeding subscores and is defined as a decrease in total score ≥30% and ≥1 point from baseline and a decrease in rectal bleeding subscore ≥1 or rectal bleeding subscore of 0 or 1.

IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor; UC=ulcerative colitis

Interested to learn more about the efficacy
and safety data for RINVOQ?